The Vasoreparative Function of Myeloid Angiogenic Cells Is Impaired in Diabetes Through the Induction of IL1β

Stem Cells
Sarah E J ChambersReinhold J Medina

Abstract

Myeloid angiogenic cells (MACs) promote revascularization through the paracrine release of angiogenic factors and have been harnessed as therapeutic cells for many ischemic diseases. However, their proangiogenic properties have been suggested to be diminished in diabetes. This study investigates how the diabetic milieu affects the immunophenotype and function of MACs. Both MACs isolated from diabetic conditions and healthy cells exposed to a diabetic environment were used to determine the potential of MACs as a cell therapy for diabetic-related ischemia. MACs were isolated from human peripheral blood and characterized alongside proinflammatory macrophages M (LPS + IFNγ) and proangiogenic macrophages M (IL4). Functional changes in MACs in response to high-d-glucose were assessed using an in vitro 3D-tubulogenesis assay. Phenotypic changes were determined by gene and protein expression analysis. Additionally, MACs from type 1 diabetic (T1D) patients and corresponding controls were isolated and characterized. Our evidence demonstrates MACs identity as a distinct macrophage subtype that shares M2 proangiogenic characteristics, but can be distinguished by CD163hi expression. High-d-glucose treatment significantly reduced MACs proang...Continue Reading

References

Feb 25, 2003·Proceedings of the National Academy of Sciences of the United States of America·Elena VoronovRon N Apte
Sep 6, 2005·Stem Cells·Eva RohdeDirk Strunk
Oct 4, 2005·Journal of Molecular and Cellular Cardiology·Carmen UrbichStefanie Dimmeler
Apr 12, 2007·American Journal of Physiology. Endocrinology and Metabolism·Mohan R DasuIshwarlal Jialal
Sep 16, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Yaron CarmiRon N Apte
Mar 1, 2007·Future Cardiology·James S Mills, Sunil V Rao
Jun 18, 2010·Investigative Ophthalmology & Visual Science·Reinhold J MedinaAlan W Stitt
Jun 3, 2011·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·David M LeistnerBirgit Assmus
May 9, 2013·EMBO Molecular Medicine·Ashish S PatelBijan Modarai
Aug 13, 2013·Immunobiology·Sarah E J ChambersAlan W Stitt
Mar 29, 2014·Circulation. Cardiovascular Interventions·Renate de JongHenricus J Duckers
Apr 1, 2014·Heart, Lung & Circulation·Haiying ChenLe-Xin Wang
Mar 31, 2015·Journal of Cellular Physiology·Toshie Kanayasu-ToyodaTeruhide Yamaguchi
Oct 28, 2015·Stem Cells·Ashay D BhatwadekarMaria B Grant
Feb 6, 2016·Physiological Reports·Sarah WitkowskiRachel Burgess
Mar 16, 2017·Stem Cells Translational Medicine·Reinhold J MedinaAlan W Stitt
Aug 29, 2017·The New England Journal of Medicine·Paul M RidkerUNKNOWN CANTOS Trial Group

❮ Previous
Next ❯

Citations

Nov 5, 2019·Journal of Cellular Biochemistry·Yuzhuo WangMin Hu
Jan 19, 2020·Journal of Biochemical and Molecular Toxicology·Jie Zhou, Cong Sun
Oct 15, 2019·Current Eye Research·Pietro Maria BertelliReinhold J Medina
Jan 21, 2021·Nature Reviews. Endocrinology·David A AntonettiAlan W Stitt
Feb 2, 2021·Stem Cells Translational Medicine·Stuart P Atkinson
Aug 17, 2020·Cellular Immunology·Hiba Yaseen, Mogher Khamaisi
Aug 14, 2021·Heart Failure Reviews·Aneta MoskalikAnna Ratajska

❮ Previous
Next ❯

Datasets Mentioned

BETA
GSE18686

Methods Mentioned

BETA
flow cytometry
biopsy

Software Mentioned

FlowJo
MOBILE
TOPCARE
GraphPad Prism
ImageJ

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.